Descrizione del progetto DEENESFRITPL Un innovativo biomateriale per una migliore terapia cellulare in seguito a infarto cardiaco La terapia cellulare post-infarto cardiaco ha mostrato risultati promettenti in termini di riduzione delle dimensioni di questa necrosi. Essa, tuttavia, non può invertire il danno al miocardio e la fibrosi. L’obiettivo del progetto HepEDOT, finanziato dall’UE, è quello di promuovere la rimuscolarizzazione cardiaca migliorando la ritenzione delle cellule dopo la terapia e superando i potenziali effetti collaterali come l’aritmia indotta dall’innesto. A questo scopo, i ricercatori testeranno un substrato biodegradabile costituito di un biomateriale a base di eparina capace di sostenere le cellule cardiache e di ottimizzare la conduttività elettrica. I risultati potrebbero migliorare la terapia cellulare cardiaca quale intervento terapeutico a seguito di infarto cardiaco. Mostra l’obiettivo del progetto Nascondi l’obiettivo del progetto Obiettivo Cell therapy has emerged as a promising therapeutic strategy for cardiac repair, showing modest cardiomyocyte protection and infarct size reduction. It is under debate whether these outcomes are due to the implanted cells or their paracrine factors, as cells are scarce within a few weeks post-implantation. Regardless, this is still not sufficient to promote cardiac remuscularization and reverse medium to severe myocardium injury and fibrosis. Improved cell retention has been achieved with a substantial bulk of implanted cells, but highly associated to graft-induced arrhythmia, representing a significant challenge for clinical translation. The present study seeks to promote cardiac remuscularization after infarct, by improving the retention of cardiac cells and their paracrine factors without causing graft-induced arrhythmia. To do so, a conductive, self-doping and biodegradable oligoEDOT-heparin biomaterial will be synthesized and studied on in vitro and in vivo cardiac infarct models. The conductive EDOT oligomer moiety is envisaged to act as an electrical sink to shield the cardiac tissue from mismatched electromechanical impulses, while heparin will facilitate cardiac cell support and loading of regenerative factors, besides its recently documented doping capacity. The results of this fellowship are expected to overcome low cell retention and graft-induced arrhythmia, two of the biggest obstacles for translation in cardiac cell therapy, but also contribute with new insights regarding conductivity in materials and biological systems, to multiple fields of materials chemistry, medicine and bioelectronics. The world-class academic environment, collaborations and combined interdisciplinary expertise in biomaterials and cardiovascular sciences make the proposed fellowship activities ideally placed for enhancing my career prospects and consolidating my host and Europe in a leading position for translational research. Campo scientifico scienze mediche e della salutemedicina clinicacardiologiamalattie cardiovascolariaritmia cardiacaingegneria e tecnologiabiotecnologia industrialebiomaterialescienze mediche e della salutebiotecnologia medicatecnologie cellulari Programma(i) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Argomento(i) MSCA-IF-2018 - Individual Fellowships Invito a presentare proposte H2020-MSCA-IF-2018 Vedi altri progetti per questo bando Meccanismo di finanziamento MSCA-IF-EF-ST - Standard EF Coordinatore IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Contribution nette de l'UE € 224 933,76 Indirizzo South kensington campus exhibition road SW7 2AZ London Regno Unito Mostra sulla mappa Regione London Inner London — West Westminster Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 0,00